RCMI Coordinating Center (RCMI CC) Header Logo

Connection

David A. Foster to Sirolimus

This is a "connection" page, showing publications David A. Foster has written about Sirolimus.
Connection Strength

5.044
  1. Mukhopadhyay S, Frias MA, Chatterjee A, Yellen P, Foster DA. The Enigma of Rapamycin Dosage. Mol Cancer Ther. 2016 Mar; 15(3):347-53.
    View in: PubMed
    Score: 0.546
  2. Saqcena M, Patel D, Menon D, Mukhopadhyay S, Foster DA. Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle. Cell Cycle. 2015; 14(14):2285-92.
    View in: PubMed
    Score: 0.516
  3. Chatterjee A, Mukhopadhyay S, Tung K, Patel D, Foster DA. Rapamycin-induced G1 cell cycle arrest employs both TGF-? and Rb pathways. Cancer Lett. 2015 May 01; 360(2):134-40.
    View in: PubMed
    Score: 0.507
  4. Mukhopadhyay S, Chatterjee A, Kogan D, Patel D, Foster DA. 5-Aminoimidazole-4-carboxamide-1-?-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells. Cell Cycle. 2015; 14(20):3331-9.
    View in: PubMed
    Score: 0.504
  5. Le Gendre O, Sookdeo A, Duliepre SA, Utter M, Frias M, Foster DA. Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells. Mol Cancer Res. 2013 May; 11(5):474-81.
    View in: PubMed
    Score: 0.443
  6. Yellen P, Chatterjee A, Preda A, Foster DA. Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-?-dependent G1 cell cycle arrest. Cancer Lett. 2013 Jun 10; 333(2):239-43.
    View in: PubMed
    Score: 0.441
  7. Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, Rodrik-Outmezguine V, Foster DA. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle. 2011 Nov 15; 10(22):3948-56.
    View in: PubMed
    Score: 0.406
  8. Foster DA, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle. 2009 Apr 01; 8(7):1026-9.
    View in: PubMed
    Score: 0.338
  9. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol. 2009 Mar; 29(6):1411-20.
    View in: PubMed
    Score: 0.332
  10. Foster DA, Gadir N. [Can defective TGF-Beta signaling be an Achilles heel in human cancer?]. Ai Zheng. 2008 Aug; 27(8):882-4.
    View in: PubMed
    Score: 0.323
  11. Chen Y, Zheng Y, Foster DA. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene. 2003 Jun 19; 22(25):3937-42.
    View in: PubMed
    Score: 0.227
  12. Chakraborty S, Utter MB, Frias MA, Foster DA. Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin. Cancer Lett. 2021 12 01; 522:164-170.
    View in: PubMed
    Score: 0.201
  13. Saqcena M, Menon D, Patel D, Mukhopadhyay S, Chow V, Foster DA. Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle. PLoS One. 2013; 8(8):e74157.
    View in: PubMed
    Score: 0.115
  14. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem. 2008 Dec 12; 283(50):34495-9.
    View in: PubMed
    Score: 0.082
  15. Chen Y, Rodrik V, Foster DA. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene. 2005 Jan 20; 24(4):672-9.
    View in: PubMed
    Score: 0.063
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support